{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:59:56Z","timestamp":1790805596549,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.xphs.2026.104430","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:55:56Z","timestamp":1784822156000},"page":"104430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Salbutamol sulfate and budesonide inhalation suspension for inhalation therapy: In vivo and in vitro evaluation"],"prefix":"10.1016","volume":"115","author":[{"given":"Chao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqi","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhong","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2026.104430_bib0001","first-page":"4355","article-title":"Global strategy for asthma management and prevention: interpretation of the updates in 2022","volume":"25","author":"Chun","year":"2022","journal-title":"Zhongguo Quanke Yixue"},{"key":"10.1016\/j.xphs.2026.104430_bib0002","article-title":"The paradoxes of asthma management: time for a new approach?","volume":"50","author":"O\u2019Byrne","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.xphs.2026.104430_bib0003","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01046-2019","article-title":"GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents","volume":"53","author":"Reddel","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.xphs.2026.104430_bib0004","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","article-title":"2020 Focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group","volume":"146","author":"Cloutier","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.xphs.2026.104430_bib0005","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1007\/s12325-020-01444-5","article-title":"Asthma-related health outcomes associated with short-acting \u03b22-agonist inhaler use: an observational UK study as part of the SABINA global program","volume":"37","author":"Bloom","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.xphs.2026.104430_bib0006","article-title":"Real-world patterns and implications of short-acting \u03b22-agonist use in patients with asthma in the United States","volume":"126","author":"Lugogo","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.xphs.2026.104430_bib0007","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01872-2019","article-title":"Overuse of short-acting \u03b22-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme","volume":"55","author":"Nwaru","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.xphs.2026.104430_bib0008","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02730-2021","article-title":"Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes","volume":"59","author":"Reddel","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.xphs.2026.104430_bib0009","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1007\/s12325-020-01233-0","article-title":"SABINA: an overview of short-acting \u03b22-agonist use in asthma in European Countries","volume":"37","author":"Janson","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.xphs.2026.104430_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2022.02.047","article-title":"Short-acting beta-2-agonist exposure and severe asthma exacerbations: SABINA Findings From Europe and North America","volume":"10","author":"Quint","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.xphs.2026.104430_bib0011","article-title":"Asthma progression and mortality: the role of inhaled corticosteroids","volume":"54","author":"O\u2019Byrne","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.xphs.2026.104430_bib0012","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(06)69284-2","article-title":"Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study","volume":"368","author":"Rabe","year":"2006","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.xphs.2026.104430_bib0013","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00625-2020","article-title":"SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis","volume":"56","author":"Rogliani","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.xphs.2026.104430_bib0014","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jama.2018.2769","article-title":"Association of inhaled corticosteroids and long-acting \u03b2-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis","volume":"319","author":"Sobieraj","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.xphs.2026.104430_bib0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1183\/09031936.00138707","article-title":"Global strategy for asthma management and prevention: GINA executive summary","volume":"31","author":"Bateman","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.xphs.2026.104430_bib0016","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1164\/rccm.202109-2205PP","article-title":"Global initiative for asthma strategy 2021: executive summary and rationale for key changes","volume":"205","author":"Reddel","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.xphs.2026.104430_bib0017","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","article-title":"2020 Focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group","volume":"146","author":"Cloutier","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.xphs.2026.104430_bib0018","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1183\/09031936.00178710","article-title":"Roflumilast with long-acting \u03b22-agonists for COPD: influence of exacerbation history","volume":"38","author":"Bateman","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.xphs.2026.104430_bib0019","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa2504544","article-title":"As-needed albuterol-budesonide in mild asthma","volume":"393","author":"LaForce","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xphs.2026.104430_bib0020","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12325-016-0459-6","article-title":"Chronic obstructive pulmonary disease individualized therapy: tailored approach to symptom management","volume":"34","author":"Singh","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.xphs.2026.104430_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0615","article-title":"Evaluation of budesonide-formoterol for maintenance and reliever therapy among patients with poorly controlled asthma: a systematic review and meta-analysis","volume":"5","author":"Beasley","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.xphs.2026.104430_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2024.06.2818","article-title":"Efficacy of albuterol-budesonide rescue on top of inhaled corticosteroid\/long-acting \u03b2-agonist (LABA) asthma maintenance therapy containing formoterol or other LABA (MANDALA)","volume":"166","author":"Panettieri","year":"2024","journal-title":"CHEST"},{"key":"10.1016\/j.xphs.2026.104430_bib0023","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2203163","article-title":"Albuterol\u2013budesonide fixed-dose combination rescue inhaler for asthma","author":"Papi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xphs.2026.104430_bib0024","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1021\/acs.molpharmaceut.8b01194","article-title":"Assessing physical stability of colloidal dispersions using a Turbiscan optical analyzer","volume":"16","author":"Sun","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2026.104430_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.powtec.2025.120881","article-title":"Numerical study on the effect of individual variations on inhaled drug particle deposition distribution in grouped realistic inhaler-airway models","volume":"457","author":"Zhang","year":"2025","journal-title":"Powder Technol"},{"key":"10.1016\/j.xphs.2026.104430_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.flowmeasinst.2023.102359","article-title":"The effects of temperature and humidity on the deposition of nebulized droplet in an idealized mouth-throat model","volume":"91","author":"Yang","year":"2023","journal-title":"Flow Meas Instrum"},{"key":"10.1016\/j.xphs.2026.104430_bib0027","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1002\/jps.21630","article-title":"Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution","volume":"98","author":"El-Gendy","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104430_bib0028","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.carbpol.2017.11.018","article-title":"Budesonide nanocrystal-loaded hyaluronic acid microparticles for inhalation: in vitro and in vivo evaluation","volume":"181","author":"Liu","year":"2018","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.xphs.2026.104430_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2023.102215","article-title":"Remote preconditioning combined with nebulized budesonide alleviate lipopolysaccharide induced acute lung injury via regulating HO-1 and NF-\u03baB in rats","volume":"80","author":"Zhao","year":"2023","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.xphs.2026.104430_bib0030","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.xphs.2022.10.001","article-title":"Budesonide-loaded bilosomes as a targeted delivery therapeutic approach against acute lung injury in rats","volume":"112","author":"Salem","year":"2023","journal-title":"J Pharm Sci"},{"issue":"Suppl 2","key":"10.1016\/j.xphs.2026.104430_bib0031","article-title":"The science of nebulised drug delivery","volume":"52","author":"O\u2019Callaghan","year":"1997","journal-title":"Thorax"},{"key":"10.1016\/j.xphs.2026.104430_bib0032","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pupt.2004.10.004","article-title":"In vitro comparison of nebulised budesonide (Pulmicort Respules\u00ae) and beclomethasone dipropionate (Clenil\u00ae per Aerosol)","volume":"18","author":"Vaghi","year":"2005","journal-title":"Pulm Pharmacol Ther"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926002790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926002790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:29:05Z","timestamp":1790803745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926002790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0022354926002790"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104430","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salbutamol sulfate and budesonide inhalation suspension for inhalation therapy: In vivo and in vitro evaluation","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104430","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104430"}}